journal
MENU ▼
Read by QxMD icon Read
search

Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine

journal
https://www.readbyqxmd.com/read/28818993/nuclear-medicine-training-what-now
#1
David A Mankoff, Daniel A Pryma
While the multi-disciplinary nature of nuclear medicine and clinical molecular imaging is a key strength of the specialty, the breadth of disciplines involved in the practice of nuclear medicine creates challenges for education and training. The evolution of nuclear medicine science and technology - and the practice of clinical molecular imaging and theranostics - has created a need for changes in the approach to specialty training. The broader US community of imaging physicians has been slow to accept this change, in good part due to historical divides between the nuclear medicine and radiology communities...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818992/long-half-life-89-zr-labeled-radiotracers-can-guide-in-suite-percutaneous-molecular-imaging-pet-ct-guided-biopsies-without-reinjection-of-radiotracer
#2
Francois H Cornelis, Jeremy Durack, Neeta Pandit-Taskar, Gary A Ulaner, Jason S Lewis, Michael J Morris, Stephen B Solomon
Rationale: To evaluate the feasibility of in suite Zr89 labeled radiotracer positron emission tomography-computed tomography (PET/CT)-guided biopsies performed without reinjection. Methods: From 2013-2016, 12 patients (7 males, 5 females; mean age 61 years, range 40-75) with suspected metastatic prostate or breast carcinoma on either imaging or biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using (89)Zr labeled radiotracers (mean dose: 180MBq; range: 126-189MBq) targeting prostate specific membrane antigen (PSMA) (n = 7) or human epidermal growth factor receptor 2 (HER2) (n = 5)...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818991/immune-modulation-therapy-and-imaging-workshop-report
#3
Anthony F Shields, Paula Jacobs, Mario Sznol, Michael M Graham, Ronald Germain, Lawrence Lum, Elaine Jaffee, Elisabeth G E de Vries, Sridhar Nimmagadda, Annick D Van den Abbeele, David Leung, Anna M Wu, Elad Sharon, Lalitha K Shankar
A workshop at the National Cancer Institute May 2, 2016 considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. Based on imaging, clinicians must decide if they should stop, pause, or continue treatment...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818990/clinical-use-and-utility-of-amyloid-imaging
#4
Henryk Barthel, Osama Sabri
Currently, three amyloid PET tracers are approved and commercially available for clinical use. They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer's disease (AD). Here, we review the current knowledge on the clinical use and utility of amyloid imaging. Appropriate use criteria for the clinical application of amyloid imaging are established, and most currently available data point to their validity. Visual amyloid image analysis is highly standardized. Disclosure of amyloid imaging results is desired by many cognitively impaired subjects, and seems to be safe once appropriate education is delivered to the disclosing clinicians...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818989/metabolic-imaging-of-infection
#5
Ismaheel Lawal, Jan Rijn Zeevaart, Thomas Ebenhan, Alfred Ankrah, Mariza Vorster, Hendrick Kruger, Thavendran Govender, Mike Sathekge
Metabolic imaging of infection has come to occupy a prominent place in the diagnosis and management of microbial infection. Molecular probes available for infection imaging have undergone a rapid evolution starting with the use of non-specific agents that accumulate similarly in infection, sterile inflammation and neoplastic tissue to more targeted probes that seek to identify specific microbial species. This focus review describes the metabolic and molecular imaging techniques currently available for clinical use in infection imaging and those that have demonstrated promising results in preclinical studies with the potential for clinical applications...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818988/multiregional-tumor-drug-uptake-imaging-by-pet-and-microvascular-morphology-in-end-stage-diffuse-intrinsic-pontine-glioma
#6
Sophie E M Veldhuijzen van Zanten, A Charlotte P Sewing, Arthur van Lingen, Otto S Hoekstra, Pieter Wesseling, Michaël H Meel, Dannis G van Vuurden, Gertjan J L Kaspers, Esther Hulleman, Marianna Bugiani
Inadequate tumor uptake of the vascular endothelial growth factor (VEGF) antibody bevacizumab could explain lack of effect in diffuse intrinsic pontine glioma (DIPG). Methods: By combining data from a positron emission tomography (PET) imaging study using zirconium-89((89)Zr)-labeled bevacizumab and an autopsy study, a 1-on-1 analysis of multiregional in vivo and ex vivo (89)Zr-bevacizumab uptake, tumor histology and vascular morphology in a DIPG patient was performed. Results: In vivo (89)Zr-bevacizumab measurements showed heterogeneity between lesions...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818987/response-assessment-of-68-ga-dota-e-c-rgdfk-2-pet-ct-for-lung-adenocarcinoma-patients-treated-with-nintedanib-plus-docetaxel
#7
Oscar Arrieta, Francisco O Garcia-Perez, David Michel-Tello, Laura-Alejandra Ramirez-Tirado, Quetzali Pitalua-Cortes, Graciela Cruz-Rico, Eleazar-Omar Macedo-Perez, Andres F Cardona, Jaime de la Garza-Salazar
Nintedanib is an oral angiokinase inhibitor used as a second-line treatment for non-small-cell lung cancer (NSCLC). New radiotracers, such as (68)Ga-DOTA-E-[c(RGDfK)]2, that target αvβ3 integrin might impact the clinical practice as a non-invasive method for assessing angiogenesis inhibitors. Methods: From July 2014 through October 2015, 38 patients received second-line nintedanib plus docetaxel. All the patients underwent PET/CT with (68)Ga-DOTA-E-[c(RGDfK)]2 radiotracer and blood-sample tests to quantify angiogenesis factors (FGF, VEGF and PDGF-AB) prior to and after completing 2 therapy cycles...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818986/david-vs-the-goliaths-for-the-detection-of-bone-metastases
#8
Gary A Ulaner
No abstract text is available yet for this article.
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818985/somatostatin-antagonists-for-radioligand-therapy-of-non-endocrine-tumors
#9
Elif Hindie, Paolo Zanotti-Fregonara, Clément Morgat
No abstract text is available yet for this article.
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818984/pseudo-reference-regions-for-glial-imaging-with-11-c-pbr28-investigation-in-two-clinical-cohorts
#10
Daniel Strakis Albrecht, Marc David Normandin, Sergey Shcherbinin, Dustin W Wooten, Adam J Schwarz, Nicole R Zurcher, Vanessa N Barth, Nicolas J Guehl, Oluwaseun Johnson-Akeju, Nazem Atassi, Mattia Veronese, Federico Turkheimer, Jacob M Hooker, Marco Luciano Loggia
The translocator protein (TSPO) is a commonly used imaging target to investigate neuroinflammation. While TSPO imaging demonstrates great promise, its signal exhibits substantial interindividual variability, which needs to be accounted for to uncover group effects that are truly reflective of neuroimmune activation. Recent evidence suggests that relative metrics computed using pseudo-reference approaches can minimize within-group variability, and increase sensitivity to detect physiologically meaningful group differences...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28818983/current-concepts-in-68-ga-dotatate-nen-imaging-interpretation-biodistribution-dosimetry-and-molecular-strategies
#11
Lisa Bodei, Valentina Ambrosini, Ken Herrmann, Irvin Modlin
(68)Ga-DOTATATE PET/CT provides information of the location(s) of somatostatin receptor expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history, the histopathology and biomarker information as well as grade, stage and prior imaging. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false positive results...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#12
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28798033/a-prospective-study-comparing-99m-tc-hdp-planar-bone-scintigraphy-and-whole-body-spect-ct-with-18-f-fluoride-pet-ct-and-18-f-fluoride-pet-mri-for-diagnosing-bone-metastases
#13
Johan Löfgren, Jann Mortensen, Sine Hvid Rasmussen, Claus Madsen, Annika Loft, Adam Espe Hansen, Peter Oturai, Karl Erik Jensen, Mette Louise Mørk, Michala Reichkendler, Liselotte Højgaard, Barbara M Fischer
We prospectively evaluate and compare the diagnostic performance of (99m)Tc-HDP planar bone scintigraphy (pBS), (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/CT and (18)F-NaF PET/MRI for the detection of bone metastases. Methods: 117 patients with histologically proven malignancy referred for clinical pBS were prospectively enrolled. pBS and whole-body SPECT/CT were performed followed by (18)F-NaF PET/CT within 9 days. (18)F-NaF PET/MRI was also performed in 46 patients. A "truth panel" including clinical follow-up served as standard of reference...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28798032/improved-estrogen-receptor-assessment-by-pet-using-the-novel-radiotracer-4fmfes-in-er-breast-cancer-patients-an-ongoing-phase-ii-clinical-trial
#14
Michel Paquette, Éric Lavallée, Serge Phoenix, René Ouellet, Helena Senta, Johan E van Lier, Brigitte Guérin, Roger Lecomte, Éric E Turcotte
Following encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) positron emission tomography (PET) radiotracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES), a phase II clinical trial was initiated to compare the PET imaging diagnostic potential of 4FMFES to 16α-[(18)F]fluoroestradiol (FES) in ER positive (ER+) breast cancer patients. Methods: Patients diagnosed with ER+ breast cancer (n = 31) were recruited for this study, including six patients that undertook mastectomy and/or axillary node dissection...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28798031/repeated-lu-177-psma-617-radioligand-therapy-using-treatment-activities-up-to-9-3-gbq
#15
Hendrik Rathke, Frederik L Giesel, Paul Flechsig, Klaus Kopka, Walter Mier, Markus Hohenfellner, Uwe Haberkorn, Clemens Kratochwil
Current treatment protocols for (177)Lu-PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness have not yet been proven clinically. We retrospectively report our clinical observations using four different treatment activities. Methods: Forty patients with advanced prostate cancer and positive uptake in PSMA-imaging were treated in fractions of 4 GBq / 80 nmol, 6 GBq / 120 nmol, 7.4 GBq / 150 nmol or 9.3 GBq / 150 nmol (177)Lu-activity / precursor-amount (n = 10, respectively) every 2 months...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775206/clinical-molecular-imaging-of-chemokine-receptor-cxcr4-expression-in-atherosclerotic-plaque-using-68-ga-pentixafor-pet-correlation-with-cardiovascular-risk-factors-and-calcified-plaque-burden
#16
Desiree Weiberg, James T Thackeray, Guenter Daum, Jan M Sohns, Saskia Kropf, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin
The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4+ cell types in cardiovascular diseases including atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of (68)Ga-Pentixafor, a specific CXCR4 ligand for positron emission tomography (PET). Methods: Data of fifty-one patients who underwent (68)Ga-Pentixafor PET/computed tomography (PET/CT) for non-cardiovascular indications were retrospectively analyzed...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775205/therapy-related-hematological-malignancies-after-peptide-receptor-radionuclide-therapy-with-177-lu-dota-octreotate-incidence-course-predicting-factors-in-patients-with-gep-nets
#17
Hendrik Bergsma, Kirsten van Lom, Mark Konijnenberg, Boen Kam, Jaap Teunissen, Wouter de Herder, Eric Krenning, Dik Kwekkeboom
Peptide Receptor Radionuclide Therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent dysfunction of the hematopoietic system after PRRT with (177)Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: The incidence and course of persistent hematological dysfunction (PHD) was analyzed in 274 (=GEP-NET) out of 367 patients with somatostatin receptor-positive tumors. PHD was defined as diagnosis of Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myeloproliferative Neoplasms (MPN), Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN) or otherwise unexplained cytopenia (for more than 6 months)...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775204/impact-of-endothelial-tspo-on-the-quantification-of-18-f-dpa-714
#18
Catriona Wimberley, Sonia Lavisse, Vincent Brulon, Marie-Anne Peyronneau, Claire Leroy, Benedetta Bodini, Philippe Remy, Bruno Stankoff, Irene Buvat, Michel Bottlaender
(18)F-DPA-714 is a second generation tracer for positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO), a marker of neuroinflammation. Analysis and interpretation of TSPO PET are challenging especially due to a basal expression of TSPO. The aim of this study was to evaluate a compartmental model which accounts for endothelial TSPO binding on PET scans from a cohort of healthy subjects. Methods: Fifteen healthy subjects (9 high-affinity binders and 6 mixed-affinity binders) underwent (18)F-DPA-714 PET scans with arterial blood sampling and metabolite analysis...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775203/immunohistochemical-validation-of-psma-expression-measured-by-68-ga-psma-pet-ct-in-primary-prostate-cancer
#19
Nadine Woythal, Ruza Arsenic, Carsten Kempkensteffen, Kurt Miller, Jan-Carlo Janssen, Kai Huang, Marcus R Makowski, Winfried Brenner, Vikas Prasad
Aim: Gallium 68 ((68)Ga) prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) has a proven role in staging and restaging of prostate cancer (PCA) patients. The aims of this study were to evaluate the association of intraprostatic (68)Ga-PSMA PET/CT (PET) findings and prostate specific membrane antigen (PSMA) expression in immunohistochemical staining (IHC) and generate a cut-off value for the differentiation between benign prostate tissue from PCA. Methods: Data of 31 patients (mean 67...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28775202/pet-mr-imaging-in-the-diagnosis-of-hormone-producing-pituitary-micro-adenoma-a-prospective-pilot-study
#20
Hao Wang, Bo Hou, Lin Lu, Ming Feng, Jie Zang, Shaobo Yao, Feng Feng, Renzhi Wang, Fang Li, Zhaohui Zhu
Purpose: This study was designed to evaluate positron emission tomography/magnetic resonance (PET/MR), using (18)F-FDG and (68)Ga-DOTATATE as tracers, in the detection of hormone-producing pituitary micro-adenoma, where diagnosis is difficult using magnetic resonance imaging (MRI) alone. Methods: A total of 37 patients with elevated hormone levels were recruited, including 19 patients with undiagnosable primary pituitary tumors and 18 patients with suspected recurrent pituitary adenomas (PAs). Patients underwent (18)F-FDG PET/MR and (68)Ga-DOTATATE PET/MR within one week...
August 3, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
journal
journal
20164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"